An objective case definition of lipodystrophy in HIV-infected adults: A case-control study

Lancet

Volumn 361, Issue 9359, 2003, Pages 726-735

  Carr, Andrew ^a,e   Emery, S ^b,f   Law, M ^b,i   Puls, R ^b   Lundgren, J D ^c   Powderly, W G ^d   Barr, D ^e   Cooper, D A ^b   Grinspoon, S ^f   Ioannidis, J ^g   Lewis, R ^h   Lichtenstein, K ⁱ   Murray, J ^j   Pizzuti, D ^k   Rozenbaum, W ^l   Schambelan, M ^m   Moore, A ^b   Miller, J ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c HVIDOVRE HOSPITAL   (Denmark)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Forum for Collaborative HIV Research   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF IOANNINA   (Greece)

^h AGOURON PHARMACEUTICALS INC   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^k BRISTOL MYERS SQUIBB   (United States)

^l HÔPITAL ROTHSCHILD   (France)

^m UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AGE; ARTICLE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; LIPOMATOSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

EID: 0037333717     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12656-6     Document Type: Article

References (32)

1. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;51-58.
2. Lo J.C., Mulligan K., Tai V.W., Algren H., Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 351:1998;867-870.
3. Carr A., Samaras K., Thorisdottir A., Kaufmann G., Chisholm D.J., Cooper D.A. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus. Lancet. 353:1999;2093-2099.
4. Carr A., Miller J., Law L., Cooper D.A. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 14:2000;25-32.
5. Thiebaut R., Daucourt V., Mercie P., et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine cohort, France, 1999. Clin Infect Dis. 31:2000;1482-1487.
6. Mallal S.A., John M., Moore C.B., et al. Contribution of nucleosides analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 14:2000;1309-1316.
7. Martinez E., Mocroft A., Garcia-Viejo M.A., et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 357:2001;592-598.
8. Lichtenstein K.A., Ward D.J., Moorman A.C., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 15:2001;1389-1398.
9. Hadigan C., Meigs J., Corcoran C., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 32:2001;130-139.
10. van der Valk M., Gisolf E.H., Reiss P., et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 15:2001;847-855.
11. Fellay J., Boubaker K., Lederberger B., et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 358:2001;1322-1327.
12. Duran S., Savs M., Spire B., et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 15:2001;2441-2444.
13. Ammassari A., Murri R., Pezzotti P., et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 8:2001;445-449.
14. Walli R., Herfort O., Michl G.M., et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1-infected patients. AIDS. 12:1998;167-174.
15. Yarasheski K.E., Tebas P., Sigmund C., et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr Hum Retrovirol. 21:1999;209-216.
16. Egger E., Junghans C., Friis-Møller N., Lundgren J.D. Highly active antiretroviral therapy and coronary heart disease: the need for perspective. AIDS. 15:(suppl 5):2001;S193-S202.
17. Saint-Marc T., Partisani M., Poizot-Martin I., et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 14:2000;37-49.
18. Kingsley L, Smit E, Riddler S, et al. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS). In: Abstracts of the 8th conference on retrovirus and opportunistic infections. Chicago, February, 2001 (abstract 538).
19. Belloso W.H., Quiros R.E., Ivalo S. A., et al. Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients. J Acquir Immune Defic Syndr. 32:2003;104-111.
20. Martínez E., Bianchi L., García-Viejo M.A., Concepción Bru C., Gatell J.M. Sonographic assessment of regional fat in HIV-1-infected people. Lancet. 356:2001;1412-1413.
21. Roche R., Poizot-Martina I., Yazidi C.M.-E., et al. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS. 16:2002;13-20.
22. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 50:2001;1378-1388.
23. Dowell P., Flexner C., Kwiterovich P.O., Lane M.D. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem. 275:2000;41325-41332.
24. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosis. Arthritis Rheum. 25:1982;1271-1277.
25. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
26. Shekelle P.G., Woolf S.H., Eccles M., Grimshaw J. Developing guidelines. BMJ. 318:1999;593-596.
27. Carr A., Workman C., Smith D., et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 288:2002;207-215.
28. Hyams K.C. Developing case definitions for symptom-based conditions: the problem of specificity. Epidemiol Rev. 20:1998;148-156.
29. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 287:2002;356-359.
30. National cholesterol education programme. Framingham cardiovascular risk equation. http://hin.nhlbi.nih.gov/atpiii/calculator.asp . (Accessed August 20, 2002).
31. Grunfeld C. Basic science and metabolic disturbances. In: Abstracts of the 14th International AIDS Conference, Barcelona, Spain, July 9, 2002 (abstract TuOr158).
32. Carr A. Improving the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet. 360:2002;81-85.